RYZ101 for progressive or recurrent meningioma
Part of Brain & nervous system, Cancer clinical trials.
This trial is testing an investigational drug, RYZ101, for people with a type of brain tumor called meningioma that has grown back or not responded to other treatments. The goal is to see if RYZ101 can help stop the tumor from growing, and to check its safety. It might be an option if you have already had surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of brain tumor called a meningioma that has grown despite treatment.
- You have completed or cannot have standard treatments like surgery or radiation.
- You are willing to have regular MRI scans.
- Your overall health and organ function meet the study's criteria.
- You are able to attend study visits and follow the plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
This trial offers expanded access to an experimental treatment (RZ-001) for people with recurrent glioblastoma (a type of brain cancer) that has grown again after initial treatment. It is for those who cannot join other clinical trials and aims to provide possible treatment options when standard ones have failed.
This trial tests a new drug, SYHA1813, for people whose high-grade meningioma has come back or gotten worse after standard treatments like surgery and radiation. The goal is to see if this drug can help control the tumor and improve outcomes.
Hear when a new Recurrent Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.